The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

Regeneron and Illumina have joined a major ... record data and updated daily – which covers more than 120 million people in the US, harvesting anonymised patient care information from tens ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

For the 10th anniversary of America’s Best Large and Midsize Employers, Forbes is recognizing 77 Best Employer ...